High Quality Primaquine Diphosphate CAS 63-45-6

• Function: Vitamins and Minerals Deficiency Drug
• Grade Standard: Medicine Grade
• Type: Chemical Reagent
• State: Powder
• Volatile: Not Volatile
• CAS: 63-45-6
• Model NO.: py0333
• Mf.: C15h27n3o9p2
• Standard: USP Bp Ep Cp
• MOQ: 1kg
• Transport Package: 25kg/Drum
• Specification: 99%
• Trademark: puya
• Origin: China
• Production Capacity: 10ton/Year

Product Description

Primaquine Diphosphate CAS 63-45-6
 

Product Name	Primaquine diphosphate
Synonyms	8-(4-amino-1-methylbutylamino)-6-methoxydiphosphatesalt;PRIMAQUINEPHOSPHATE,USP;4-pentanediamine,n(sup4)-(6-methoxy-8-quinolinyl)-phosphate;8-((4-amino-1-methylbutyl)amino)-6-methoxy-quinolinphosphate;Primaquinediphosphatesalt,8-(4-Amino-1Chemicalbook-methylbutylamino)-6-methoxydiphosphatesalt;1,4-Pentanediamine,N(sup4)-(6-methoxy-8-quinolinyl)-,phosphate(1:2);N-(6-Methoxyquinolin-8-yl)pentane-1,4-diaminephosphoricacid;,8-((4-amino-1-methylbutyl)amino)-6-methoxy-,phosphate(1:2)
MOQ	1kg
CAS	63-45-6
Appearance	Orange red
Molecular Formula	C15H27N3O9P2
Molecular Weight	455.34
Assay	>99%
Application	For research purpose only
Packing	25kg/drum
Storage	Store in a well-closed,light-resistant container
Remarks	NA
Custom synthesis	Available

Primaquine Diphosphate  is a medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. It is an alternative treatment for Pneumocystis pneumonia together with clindamycin.

Function

1.Primaquine diphosphate is primarily used to prevent relapse of malaria due to Plasmodium vivax and Plasmodium ovale.

2.Use in combination with quinine or chloroquine each of which is very effective at clearing P. vivax from blood, improves outcomes; they appear to also potentiate the action of primaquine.

3.Primaquine diphosphate is also used in the treatment of Pneumocystis pneumonia (), a fungal infection commonly occurring in people with AIDS and, more rarely, in those taking immunosuppressive drugs. To treat effectively, it is usually combined with clindamycin.

4.Primaquine diphosphate has not been studied extensively in people 65 and older so it is not known if dosing should be adjusted for this population.